Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company pioneering therapies targeting the α7 nicotinic acetylcholine receptor to treat neuropsychiatric conditions such as social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD). Despite recent setbacks, its lead candidate BNC210 shows promise for rapid relief without sedation or addiction risks. Collaborations with Merck on complementary positive allosteric modulators enhance its pipeline breadth, while legacy oncology licenses provide ancillary revenue streams. The company's financial profile reflects ongoing developmental expenditure with improving cash flow dynamics but necessitates continued capital infusion to sustain operations amid milestone-driven revenue potential. Return metrics such as ROE remain negative, and no dividends or buybacks have been declared, consistent with its clinical-stage status.